Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Alemtuzumab High-Risk Patients	76
Overall Study	STARTED	Conventional High-Risk Patients	70
Overall Study	STARTED	Alemtuzumab Low- Risk Patients	175
Overall Study	STARTED	Conventional Low-Risk Patients	180
Overall Study	Received Treatment	Alemtuzumab High-Risk Patients	70
Overall Study	Received Treatment	Conventional High-Risk Patients	69
Overall Study	Received Treatment	Alemtuzumab Low- Risk Patients	164
Overall Study	Received Treatment	Conventional Low-Risk Patients	171
Overall Study	COMPLETED	Alemtuzumab High-Risk Patients	51
Overall Study	COMPLETED	Conventional High-Risk Patients	48
Overall Study	COMPLETED	Alemtuzumab Low- Risk Patients	134
Overall Study	COMPLETED	Conventional Low-Risk Patients	140
Overall Study	NOT COMPLETED	Alemtuzumab High-Risk Patients	25
Overall Study	NOT COMPLETED	Conventional High-Risk Patients	22
Overall Study	NOT COMPLETED	Alemtuzumab Low- Risk Patients	41
Overall Study	NOT COMPLETED	Conventional Low-Risk Patients	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00113269/flow